EliteTrading

$SPX $SPY H&S .. 660 is key 🔑 I'm bearish until we break and hold that. Over 660 it could get wild, but ... $QQQ $NVDA

@JohnLoc18 H&S 👀

I’ll try again, $SPY divergence right here, target 654-653 by end of day. Nfa.

@JohnLoc18 Yeah, nonstop rejections on higher time frames. It's too early for bulls to get excited, I've been saying this for weeks.

$SPX $SPY isn't bullish yet. I said last week that 660 break/hold is key. Multiple bear flags and rejections. $QQQ $NVDA $AAPL

$SPX $SPY Gap still.

@cameron_doproxy How is it a scam? Legit been using it daily for 2 years for free. It's cool if you don't want to capitalize.

@EliteGainzTrade another algo scam

$SPX $SPY Our #Algo will be live streamed FREE on Youtube soon. Eeeeeasy money. Look at our 3 entries. 🤑🔥 Follow for the link! $AAPL $WMT $NVDA $MSFT

@MomentumScans Thin float, this one could gain traction again fast.

✅ $ARTL Reversal watch . Just locked in a fully funded clinical study for ART27.13 in glaucoma — expanding into the massive $16.3B market. ✅ Ethics & MHRA approved ✅ Led by world-renowned expert ✅ First patients Q2 2026 ✅ Pipeline diversification with strong momentum (+50% surge on news) ✅ Watch for reversal after yesterdays pullback news-events/press-releases/detail/178/artelo-announces-third-party-fully-funded-clinical-study-agreement-to-evaluate-art27-13-in-glaucoma-patients Advertisement disclaimer in linktree .

@MomentumScans Yes! Bounce and sold off a bit, but potential here with more inflow on this low float

@EliteGainzTrade Markets challenging it today but it wants to bounce ! Likely undervalued with the latest news

News today with a pop, and now gap has filled. Watch for volume inflow and a continuation. 📈 $ARTL FULLY FUNDED STUDY + CLINICAL MOMENTUM BUILDING. Artelo Biosciences is stacking multiple bullish catalysts with its insane pipeline! 🔬 Clinical Progress: ART26.12 (pain program) ▪️ Positive Phase 1 human data ▪️ Favorable safety + dosing profile ⏳️ Moving toward next-stage trials in 2026 ART27.13 (cancer cachexia) ▪️ Positive Phase 2 interim results ▪️ Improved body weight + activity vs placebo ▪️ Large unmet need in oncology space 💰 NEW CATALYST: FULLY FUNDED GLAUCOMA STUDY Third party funded clinical study announced, expanding pipeline into $16B+ glaucoma market.No funding risk for this program. 🧠 CBD BREAKTHROUGH ANGLE (ART12.11) Proprietary pharma grade CBD candidate which improved bioavailability vs standard CBD.. now positioned for clinical trials! My Thoughts: Multiple opportunitiesin a massive and growing industry from (pain, cancer, CBD, glaucoma)! Positive clinical data across programs + FULLY funded, so LOW dilution risk. News Link: elite.finviz.com/news/320044/ar…⁠ Peers - $IMNN $ITRM $ATON $BFRI $LIAN $JAGX $CNSP $XRTX $SNOA $IGC $ZYNE $ACAD Communicated-Disclaimer- tinyurl.com/yyvaf8p6

@TheShortSqueezy Super cool image that depicts what this company is doing. Revenue and Profit climbing, but a low market cap.

$BNZI: Powering the Next Generation of AI Driven Marketing 📈 Banzai International is a MarTech SaaS company building an AI-driven platform for video, webinars, and customer engagement through strategic acquisitions. Latest News / Milestones 🔸 Transformational acquisition: BNZI reached a deal to acquire ConnectAndSell assets, a profitable AI sales acceleration 🔸 Revenue inflection: The deal is expected to more than double annual revenue, adding $15M+ in topline 🔸 AI expansion: Adds real-time sales engagement + AI capabilities, strengthening the platform 🔸 Strong prior growth: BNZI recently reported 163% YoY revenue growth Key Catalysts ⏳ Revenue step change from ConnectAndSell integration ⏳ Expansion into AI powered sales acceleration alongside marketing ⏳ Margin expansion potential from profitable acquired assets 🗓️March 31 conference call (Q4 2025 results, initiatives, and forward milestones) With the global MarTech and digital marketing market projected to exceed $500B+, BNZI is targeting a massive and rapidly expanding opportunity. Communcated Disclaimer: tinyurl.com/Therealshortsq… Sector Peers: $ZM $MSFT $GOOGL $DOCU $ADBE $TEAM $CRM $SHOP $NOW $TWLO

@JulesTradesInc Hot 🔥

$CVX 📊 Setup Overview ▪️ Clear bullish channel forming ▪️ Consistent higher highs + higher lows ▪️ Volume picking up on moves higher ▪️ Riding above key moving averages 🎯 Trade Plan ▪️ Key Level: $200 must hold ▪️ Upside Targets: $215 - $225 ▪️ Bias: Bullish continuation $SPX $QQQ $NVDA $SPY

🚨 Noteable charts with strength to track into end of day. $PAYS $MKDW $SIDU

🚨 Elite Market Momentum Snapshot 🚀 Top Gainers $RMSG $ROMA $PAYS $MKDW $SIDU $BZAI 💎 New Highs $ROMA $ELVN $SATL $MPTI 📊 Market Snapshot ▪️ $SPY → $660.9 (+1.9%) ▪️ Gold #Gold → $2,180 (+0.4%) ▪️ Silver #Silver → $24.5 (+0.6%) ▪️ Oil (WTI) → $81.5 (+0.8%) ▪️ Bitcoin #Bitcoin → $67,000 (+2.1%)

Banger .. 655.69🤑

$SPX $SPY GAP ⤵️👀

NEWS today! 💰 $ARTL BULL CASE .. Massive target market exceeding 120 BILLION dollars for Pain Management, Cancer, Glaucoma! 🌎 Global Market Size: ▪️ Pain Management: $80B+ ▪️ Cancer Support (Cachexia): $3B–$5B+ ▪️ CBD / Cannabinoid Pharma: $20B–$50B+ (a fast growing industry) ▪️ Glaucoma / Eye Care: $15B–$20B+ Catalysts: Multi-Program Pipeline ✔️Massive Market Potential Pain + cancer + eye disease = multi-billion dollar with expansion potential. ✔️ Positive Clinical Signals Encouraging data in all programs. ✔️ Fully Funded Study. Financial backing is often the missing link, but not here! Glaucoma program backed externally so less dilution risk. ✔️ CBD Pharma Angle Pharmaceutical grade CBD equala higher-value vs retail CBD. A #CBD name to watch! Peers - $IMNN $ITRM $ATON $BFRI $LIAN $JAGX $CNSP $XRTX $SNOA $IGC $ZYNE $ACAD Communicated-Disclaimer- tinyurl.com/yyvaf8p6

@JulesTradesInc Absolutely. A low float since RS.

@EliteGainzTrade Solid volume for this low float 👀

🚨 News 🚨 $ARTL SURGING ON $16.3B MARKET EXPANSION + FUNDED STUDY! Artelo is gaining momentum after announcing a major pipeline expansion + capital-efficient clinical move! 🔑 Key Points: ▪️ Entering $16.3B glaucoma market 👉 Expands beyond cancer + pain into a massive new opportunity. ▪️ Fully funded clinical study 👉 Backed by third parties = no direct cost to shareholders ▪️ Pipeline expansion + new indication 👉 Lead drug ART27.13 now targeting multiple indications (cancer + glaucoma). Keep this low float on watch! Peers - $IMNN $ITRM $ATON $BFRI $LIAN $JAGX $CNSP $XRTX $SNOA $IGC $ZYNE $ACAD Communicated-Disclaimer- tinyurl.com/yyvaf8p6

@traderjon01 Great stuff! Potential for a move on this low float.

$ARTL watching this one after the big recent move! 🔥 Entered into the Glaucoma market on 3/18. This is a fully funded clinical study agreement. 🔥 They just completed a reverse split this month. This reduced the float to about 708k shares. 🔥 ART12.11 (CBD cocrystal) outperforms standard CBD in absorption and consistency. 🔥 Near term catalyst: Enrollment for the ART26.12 MAD study is set for Q3 2026. 🔥They have 3 main drugs, I'll dive into each one in the next tweet. ART27.13, ART26.12 , and ART12.11. ⚠️ Small but open S-1 Disclaimer: tinyurl.com/traderjon01-ar… #advertisement ~ Paid $400 cash by a third party on 3/25/2026 for this promotion. I don't own any shares. Penny stocks are extremely high risk and volatile — NFA. Do your own due diligence. ~ $TERN $JNJ $MRK